Website
News25/Ratings0
Latest news
25 items- PREnzo Biochem Reports Third Quarter Fiscal Year 2025 ResultsFARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX:ENZB) ("Enzo" or the "Company") today announced financial results for the fiscal third quarter ended April 30, 2025. Financial Highlights The Company's third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life sciences tools space, including decreases in government grants, reduced R&D budgets, and tariffs uncertainty, as well as timing of large orders fulfillment.The Company launched approximately 100 new products during the third-quarter of fiscal year 2025, and we are
- SECEnzo Biochem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ENZO BIOCHEM INC (0000316253) (Filer)
- PREnzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential TransactionForms Special Committee of the Board to Lead Evaluation of Viable Options for Maximizing Shareholder Value Engages Independent Financial and Legal Advisors to Support Thorough Process Remains Committed to Maintaining Focus on Cost Containment, Cash Preservation and Near-Term Initiatives to Enhance Value Farmingdale, NY, April 22, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX:ENZB) ("Enzo" or the "Company") today announced that its Board of Directors (the "Board") has commenced a review of strategic alternatives after recently receiving multiple inquiries regarding a potential transaction with the Company. In connection with this process, the Board has formed a special committee of
- SECEnzo Biochem Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - ENZO BIOCHEM INC (0000316253) (Filer)
- SECSEC Form 25 filed by Enzo Biochem Inc.25 - ENZO BIOCHEM INC (0000316253) (Filer)
- SECEnzo Biochem Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ENZO BIOCHEM INC (0000316253) (Filer)
- PREnzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQXFARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced its intention to voluntarily delist its common stock from The New York Stock Exchange ("NYSE") and to have its common stock quoted on the OTCQX Best Market ("OTCQX"). Enzo provided notice of the voluntary delisting to the NYSE on March 28, 2025 and intends to timely file a notification of removal from listing on Form 25 with the Securities and Exchange Commission (the "SEC") to effect the delisting. It is anticipated that the delisting will become effective on or about April 17, 2025, with trading on OTCQX to commence on or about April 18, 2025. This announceme
- SECEnzo Biochem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ENZO BIOCHEM INC (0000316253) (Filer)
- PREnzo Biochem Reports Second Quarter Fiscal Year 2025 ResultsFARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross margin and operating profit / loss. Financial Highlights The Company's second-quarter gross margin percentage of 52% increased sequentially from 37% during Q1 2025 and increased from 49% during the second quarter of the prior year. These improvements were driven by change in revenues, cost efficiency actions completed, and mix of products sold.The Enzo Life Sciences Products segment, which excludes discontinued operations and Corporate over
- SECSEC Form 10-Q filed by Enzo Biochem Inc.10-Q - ENZO BIOCHEM INC (0000316253) (Filer)
- INSIDERDirector Radoff Bradley Louis was granted 142,897 shares, increasing direct ownership by 3% to 4,533,779 units (SEC Form 4)4 - ENZO BIOCHEM INC (0000316253) (Issuer)
- INSIDERDirector Pully Steven J was granted 142,897 shares, increasing direct ownership by 147% to 239,992 units (SEC Form 4)4 - ENZO BIOCHEM INC (0000316253) (Issuer)
- INSIDERDirector Couchman Jonathan was granted 142,897 shares (SEC Form 4)4 - ENZO BIOCHEM INC (0000316253) (Issuer)
- SECEnzo Biochem Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ENZO BIOCHEM INC (0000316253) (Filer)
- SECEnzo Biochem Inc. filed SEC Form 8-K: Other Events8-K - ENZO BIOCHEM INC (0000316253) (Filer)
- SECEnzo Biochem Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ENZO BIOCHEM INC (0000316253) (Filer)
- PREnzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing RulesFARMINGDALE, N.Y, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced that it was notified by the New York Stock Exchange (the "NYSE") that it is not in compliance with Section 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) its 30 trading-day average market capitalization was less than $50 million and its last reported stockholder's equity as of October 31, 2024 was less than $50 million and (ii) the average closing price of the Company's Common Stock (the "Common Stock") was less than $1.00 over a consecutive 30 trading-day period. The Company has a period of 18 months to cure the market capitalization and st
- PREnzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company UpdateFARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal first quarter ended October 31, 2024. First Quarter Highlights Enzo ended the first quarter with aggregate cash and cash equivalents of $47.7 million. The net cash used in operating activities during the first quarter decreased by $4.4 million compared to the prior year. The Company's first-quarter revenue of $6.2 million declined year-over-year by 20% due to declining market demand related to general continued headwinds in the life sciences tools space. Recent Events The declared special cash dividend of $0.10 per share on its
- SECSEC Form 10-Q filed by Enzo Biochem Inc.10-Q - ENZO BIOCHEM INC (0000316253) (Filer)
- INSIDERNew insider Couchman Jonathan claimed ownership of 447,237 shares (SEC Form 3)3 - ENZO BIOCHEM INC (0000316253) (Issuer)
- SECSEC Form DEF 14A filed by Enzo Biochem Inc.DEF 14A - ENZO BIOCHEM INC (0000316253) (Filer)
- SECEnzo Biochem Inc. filed SEC Form 8-K: Leadership Update8-K - ENZO BIOCHEM INC (0000316253) (Filer)
- SECEnzo Biochem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ENZO BIOCHEM INC (0000316253) (Filer)
- PREnzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash DividendFARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company's revenues in the 2024 period of $31.9 million improved year-over-year by 3%. Enzo's sales to its industrial customers, which includes biotech and pharmaceutical companies, increased 46% driven by our drug development and cell and gene therapy focus.The Company's FY24 gross margin was 46%. The prio
- SECSEC Form 10-K filed by Enzo Biochem Inc.10-K - ENZO BIOCHEM INC (0000316253) (Filer)